Advised a top-tier China Healthcare Manager in the formation of Fund VI of US$2.09 billion
Advised CBC Group in the formation of C-Bridge Healthcare Fund V of US$1.67 billion
Advised Orchid Asia Group in the formation of Fund VIII of US$1.35 billion
Advised Loyal Valley Capital in the formation of Fund III of over US$1 billion and multiple co-investment funds
Advised Sherpa Healthcare Partners in the raising of its debut USD healthcare fund and its second USD healthcare fund of over US$650 million
Advised Dayone Capital in the formation of its first USD fund of over US$630 million
Advised PAG in the formation of its second growth-focused private equity fund of US$525 million
Advised Insignia Ventures Partners in the formation of Fund III of US$516 million
Advised GL Capital on its proposed privatization of SciClone Pharmaceuticals (Holdings) Limited (HKSE: 6600), a company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange
Advised GL Capital in the formation of its third healthcare fund
